Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PCSK9 | Q8NBP7 | 3/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 5/20 | 0.32 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.31 |
| ▸ | PTAFR | P25105 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1932988 | 0.89 | PCSK9 (0.35) | PCSK9BRD4LMNAPTGDR2 | |
| SCHEMBL2315327 | 0.87 | LMNA (0.43) | PCSK9BRD4LMNAPTGDR2 | |
| SCHEMBL2319582 | 0.86 | EED (0.39) | — | |
| SCHEMBL2319229 | 0.85 | LATS1 (0.35) | PCSK9BRD4PTGDR2 | |
| SCHEMBL2320144 | 0.85 | PTGS2 (0.33) | CYP11B1CYP11B2LMNAPTGDR2 | |
| SCHEMBL2318669 | 0.85 | ALDH1A1 (0.35) | PCSK9LMNAPTGDR2 | |
| SCHEMBL27876385 | 0.84 | CYP11B1 (0.36) | CYP11B1CYP11B2MAP3K5PTAFRHTR2B | |
| SCHEMBL16244938 | 0.82 | PTGDR2 (0.42) | PCSK9BRD4PTGDR2 | |
| SCHEMBL2315168 | 0.81 | EED (0.32) | PCSK9BRD4LMNA | |
| SCHEMBL2317234 | 0.81 | SCN9A (0.40) | BRD4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140349970-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2014-11-27 | — | — | US | disclosed |
| US-20140349970-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2014-11-27 | — | — | US | disclosed |
| US-20140349970-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2014-11-27 | — | — | US | disclosed |
| US-8785639-B2 | Substituted dihydropyrazolo[3,4-D]pyrrolo[2,3-B]pyridines and methods of use thereof | ABBVIE INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8785639-B2 | Substituted dihydropyrazolo[3,4-D]pyrrolo[2,3-B]pyridines and methods of use thereof | ABBVIE INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8785639-B2 | Substituted dihydropyrazolo[3,4-D]pyrrolo[2,3-B]pyridines and methods of use thereof | ABBVIE INC. (US) | 2014-07-22 | — | — | US | disclosed |
| EP-2506713-A1 | NOVEL TRICYCLIC COMPOUNDS | Abbott Laboratories (US) | 2012-10-10 | — | — | EP | disclosed |
| US-20110190489-A1 | Novel Tricyclic Compounds | ABBOTT LABORATORIES (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110190489-A1 | Novel Tricyclic Compounds | ABBOTT LABORATORIES (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110190489-A1 | Novel Tricyclic Compounds | ABBOTT LABORATORIES (US) | 2011-08-04 | — | — | US | disclosed |
| WO-2011068899-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-09 | — | — | WO | disclosed |
| WO-2011068899-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349970-A1 | NOVEL TRICYCLIC COMPOUNDS | CCNI, IL2, IL4I1 | PCSK9 1419/4885CYP11B1 11/4885CYP11B2 9/4885 |
| US-20110190489-A1 | Novel Tricyclic Compounds | CCNI, IL2, IL4I1 | PCSK9 1419/4885CYP11B1 11/4885CYP11B2 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.